4.2 C
Oklahoma
Wednesday, February 8, 2023

Teacher Retirement System of Texas Raises Stake in Alkermes plc (NASDAQ:ALKS)

Teacher Retirement System of Texas boosted its position in Alkermes plc (NASDAQ:ALKSGet Rating) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 813,538 shares of the company’s stock after buying an additional 27,797 shares during the quarter. Teacher Retirement System of Texas owned approximately 0.50% of Alkermes worth $18,166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

- Advertisement -

→ BREAKING: Tiny biotech successfully treats blindness (From Behind the Markets)

Several other hedge funds and other institutional investors have also bought and sold shares of ALKS. Neo Ivy Capital Management purchased a new stake in Alkermes in the second quarter worth approximately $27,000. Trust Co. of Vermont purchased a new stake in Alkermes in the second quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. purchased a new stake in Alkermes in the third quarter worth approximately $34,000. Exchange Traded Concepts LLC boosted its stake in shares of Alkermes by 132.0% during the second quarter. Exchange Traded Concepts LLC now owns 1,506 shares of the company’s stock valued at $45,000 after purchasing an additional 857 shares during the period. Finally, International Biotechnology Trust PLC bought a new position in shares of Alkermes in the second quarter worth approximately $51,000. Hedge funds and other institutional investors own 96.15% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. StockNews.com cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 2nd. Bank of America raised their price target on shares of Alkermes from $27.00 to $28.00 in a report on Sunday, January 8th. JPMorgan Chase & Co. cut their price target on shares of Alkermes from $33.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, December 6th. Mizuho raised their price target on shares of Alkermes from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 22nd. Finally, Piper Sandler raised shares of Alkermes from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $26.00 to $30.00 in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.10.

Alkermes Trading Up 0.8 %

Shares of NASDAQ ALKS opened at $27.89 on Friday. Alkermes plc has a 1 year low of $21.75 and a 1 year high of $32.79. The stock has a market cap of $4.58 billion, a P/E ratio of -35.76 and a beta of 0.57. The firm has a 50-day moving average of $25.36 and a 200 day moving average of $25.16. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.24 and a quick ratio of 1.89.

Alkermes (NASDAQ:ALKSGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Alkermes had a negative net margin of 11.41% and a negative return on equity of 1.10%. The business had revenue of $252.36 million for the quarter, compared to analysts’ expectations of $271.45 million. During the same period last year, the business earned ($0.02) earnings per share. The company’s revenue was down 14.2% on a year-over-year basis. As a group, sell-side analysts expect that Alkermes plc will post -0.31 EPS for the current fiscal year.

Alkermes Company Profile

- Advertisement -

(Get Rating)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

Featured Articles

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKSGet Rating).

- Advertisement -

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Alkermes, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alkermes wasn’t on the list.

While Alkermes currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover



story by The Texas Tribune Source link

Teacher Retirement System of Texas boosted its position in Alkermes plc (NASDAQ:ALKSGet Rating) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 813,538 shares of the company’s stock after buying an additional 27,797 shares during the quarter. Teacher Retirement System of Texas owned approximately 0.50% of Alkermes worth $18,166,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

→ BREAKING: Tiny biotech successfully treats blindness (From Behind the Markets)

Several other hedge funds and other institutional investors have also bought and sold shares of ALKS. Neo Ivy Capital Management purchased a new stake in Alkermes in the second quarter worth approximately $27,000. Trust Co. of Vermont purchased a new stake in Alkermes in the second quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. purchased a new stake in Alkermes in the third quarter worth approximately $34,000. Exchange Traded Concepts LLC boosted its stake in shares of Alkermes by 132.0% during the second quarter. Exchange Traded Concepts LLC now owns 1,506 shares of the company’s stock valued at $45,000 after purchasing an additional 857 shares during the period. Finally, International Biotechnology Trust PLC bought a new position in shares of Alkermes in the second quarter worth approximately $51,000. Hedge funds and other institutional investors own 96.15% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. StockNews.com cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 2nd. Bank of America raised their price target on shares of Alkermes from $27.00 to $28.00 in a report on Sunday, January 8th. JPMorgan Chase & Co. cut their price target on shares of Alkermes from $33.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, December 6th. Mizuho raised their price target on shares of Alkermes from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, November 22nd. Finally, Piper Sandler raised shares of Alkermes from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $26.00 to $30.00 in a report on Thursday, November 3rd. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.10.

Alkermes Trading Up 0.8 %

Shares of NASDAQ ALKS opened at $27.89 on Friday. Alkermes plc has a 1 year low of $21.75 and a 1 year high of $32.79. The stock has a market cap of $4.58 billion, a P/E ratio of -35.76 and a beta of 0.57. The firm has a 50-day moving average of $25.36 and a 200 day moving average of $25.16. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.24 and a quick ratio of 1.89.

Alkermes (NASDAQ:ALKSGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Alkermes had a negative net margin of 11.41% and a negative return on equity of 1.10%. The business had revenue of $252.36 million for the quarter, compared to analysts’ expectations of $271.45 million. During the same period last year, the business earned ($0.02) earnings per share. The company’s revenue was down 14.2% on a year-over-year basis. As a group, sell-side analysts expect that Alkermes plc will post -0.31 EPS for the current fiscal year.

Alkermes Company Profile

(Get Rating)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

Featured Articles

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKSGet Rating).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Alkermes, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alkermes wasn’t on the list.

While Alkermes currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover



story by The Texas Tribune Source link

More articles

Latest article